已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.

医学 析因分析 索拉非尼 内科学 肝细胞癌 胃肠病学 肝功能 事后 外科
作者
Arndt Vogel,Ann‐Lii Cheng,Wei Shi,Seong Ho Jang,Laura E. Crotty Alexander,Xianzhang Meng,N Raphael,Stephen L. Chan
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (3_suppl): 509-509
标识
DOI:10.1200/jco.2024.42.3_suppl.509
摘要

509 Background: CARES-310 study (NCT03764293) evaluated the combination of camrelizumab, an anti-PD-1 inhibitor, and rivoceranib, a highly selective VEGFR-2 tyrosine kinase inhibitor, (cam + rivo) vs sorafenib (sora) for the treatment of uHCC. Cam + rivo significantly improved median overall survival ([mOS] 22.1 months [mo] vs 15.1 mo) and median progression-free survival ([mPFS] 5.6 mo vs 3.7 mo) compared to sora. This post-hoc analysis evaluated the impact of baseline albumin-bilirubin (ALBI) grade and Child-Pugh (CP) class on survival outcomes. Methods: In this randomized, open-label, international, multicenter, phase 3 study, patients were randomized 1:1 to receive cam 200 mg IV Q2W + rivo 250 mg PO QD (n=272) or sora 400 mg PO BID (n=271). Median overall survival (mOS), median progression free survival (mPFS), objective response rate (ORR), disease control rate (DCR), and safety were assessed by baseline ALBI grade and CP class. Results: mOS, mPFS, DCR, and ORR improved with cam + rivo vs sora regardless of baseline liver function (Table). Although treatment-related grade 3/4 AEs occurred at a greater rate in the cam + rivo arm vs the sora arm, the rate of these events was similar for patients with baseline ALBI grade 1 and grade 2 (cam + rivo, 82.1% and 81.7% vs sora, 53.9% and 54.0%, respectively). Median time-to-deterioration (mTTD) to CP class B was similar between treatment arms for ALBI grade 1 (not evaluable [NE], NE) and grade 2 (cam + rivo, 10.1 mo; sora, 10.6 mo; HR, 0.99). Conclusions: In this post-hoc analysis of Study CARES-310, the efficacy of cam + rivo was superior to sora regardless of baseline liver function as measured by both ALBI grade and CP class. Despite a higher rate of grade 3/4 AEs, there was no detrimental effect of cam +rivo on liver function in patients with both well- and moderately- preserved liver function compared to sora. These results support cam + rivo as a potential new first-line treatment option for patients with uHCC regardless of baseline liver function. Clinical trial information: NCT03764293 . [Table: see text]
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Jemma发布了新的文献求助10
2秒前
2秒前
初见发布了新的文献求助10
3秒前
aiai发布了新的文献求助10
3秒前
焦立超发布了新的文献求助10
5秒前
马户的崛起完成签到,获得积分10
6秒前
Hodlumm发布了新的文献求助10
7秒前
小瓜完成签到 ,获得积分10
9秒前
封迎松完成签到 ,获得积分10
11秒前
11秒前
wanci应助kingking采纳,获得10
12秒前
一只呆呆完成签到 ,获得积分10
12秒前
ding应助AC赵先生采纳,获得10
12秒前
15秒前
我是老大应助追寻的城采纳,获得10
16秒前
温婉的香氛发布了新的文献求助100
16秒前
JamesPei应助HelloKun采纳,获得10
18秒前
研友_VZG7GZ应助Hodlumm采纳,获得10
19秒前
General发布了新的文献求助10
20秒前
喝杯水再走完成签到,获得积分10
20秒前
21秒前
21秒前
22秒前
22秒前
向日葵完成签到,获得积分10
23秒前
阿叶同学完成签到,获得积分10
23秒前
超人爱吃菠菜完成签到,获得积分10
24秒前
陈志宏发布了新的文献求助10
25秒前
AC赵先生发布了新的文献求助10
26秒前
海盐发布了新的文献求助20
26秒前
26秒前
烟花应助高挑的小虾米采纳,获得10
27秒前
爆米花应助General采纳,获得10
27秒前
27秒前
孙鑫完成签到,获得积分10
28秒前
xia发布了新的文献求助10
29秒前
29秒前
初见完成签到,获得积分10
30秒前
追寻的城发布了新的文献求助10
31秒前
典雅千萍完成签到,获得积分20
33秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976455
求助须知:如何正确求助?哪些是违规求助? 3520548
关于积分的说明 11203728
捐赠科研通 3257156
什么是DOI,文献DOI怎么找? 1798618
邀请新用户注册赠送积分活动 877819
科研通“疑难数据库(出版商)”最低求助积分说明 806523